Aventis Closer to U.S. Approval for AIDS-Related Drug
March 26, 2004
Paris-based Aventis, France's largest drug firm, is one step closer in getting U.S. approval for Sculptra, its injectable wrinkle-filling drug for patients with AIDS-related wasting condition. An advisory panel unanimously voted to recommend Food and Drug Administration approval of Sculptra for people with HIV, while cautioning against more widespread use. Aventis estimates annual sales of the drug to be as much as 1 billion euros (US$1.2 billion).
New York Times
03.26.04; Bloomberg News
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.